Genmab A/S
GMAB
$25.10
$0.301.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 3.48B | 3.48B | 3.34B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 3.48B | 3.48B | 3.34B |
| Cost of Revenue | -- | -- | 192.27M | 192.27M | 163.27M |
| Gross Profit | -- | -- | 3.29B | 3.29B | 3.17B |
| SG&A Expenses | -- | -- | 593.72M | 593.72M | 578.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 2.28B | 2.28B | 2.23B |
| Operating Income | -- | -- | 1.21B | 1.21B | 1.11B |
| Income Before Tax | -- | -- | 1.47B | 1.47B | 1.36B |
| Income Tax Expenses | -- | -- | 178.77M | 178.77M | 195.77M |
| Earnings from Continuing Operations | -- | -- | 1.30K | 1.30K | 1.16K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 1.30B | 1.30B | 1.16B |
| EBIT | -- | -- | 1.21B | 1.21B | 1.11B |
| EBITDA | -- | -- | 1.25B | 1.25B | 1.15B |
| EPS Basic | -- | -- | 20.53 | 20.53 | 18.24 |
| Normalized Basic EPS | -- | -- | 12.92 | 12.92 | 11.98 |
| EPS Diluted | -- | -- | 20.39 | 20.39 | 18.10 |
| Normalized Diluted EPS | -- | -- | 12.83 | 12.83 | 11.89 |
| Average Basic Shares Outstanding | -- | -- | 252.51M | 252.51M | 255.19M |
| Average Diluted Shares Outstanding | -- | -- | 254.08M | 254.08M | 256.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |